首页|期刊导航|中国合理用药探索|基于FAERS数据库分析奥马珠单抗治疗儿童与成人哮喘的安全性差异

基于FAERS数据库分析奥马珠单抗治疗儿童与成人哮喘的安全性差异OA

Analysis of the Safety Differences of Omalizumab Treatment in Children and Adults with Asthma Based on the FAERS Database

中文摘要英文摘要

目的:基于美国食品药品监督管理局不良事件报告系统(FAERS),比较奥马珠单抗在儿童与成人哮喘患者中不良事件(ADE)的发生特征与风险信号差异,为临床安全用药提供更具体的指导.方法:检索 2004年1月~2025 年 3月FAERS数据库中奥马珠单抗用于哮喘治疗的ADE,采用《国际医学用语词典》28.0 版的首选术语(PT)和系统器官类别(SOC)对ADE进行描述和分类.采用报告比值比法(ROR)、比例报告比值法(PRR)、Bayesian置信传播神经网络法(BCPNN)和多项伽马Poisson分布缩减法(MGPS)进行风险信号挖掘.结果:共纳入15 141例ADE报告.在SOC水平,奥马珠单抗在儿童与成人中引起的ADE均累及27个SOC,同时满足4种算法的阳性信号为"免疫系统疾病"和"呼吸系统、胸及纵隔疾病",且"免疫系统疾病"的4种算法儿童高于成人.在PT水平,儿童"速发严重过敏反应"和成人"血压升高"的ROR阳性信号差异最为显著.儿童与成人ADE的中位发病时间分别为54天和97天.结论:奥马珠单抗在儿童与成人哮喘患者中的ADE信号特征与发生时间存在差异.儿童在免疫系统与呼吸系统相关ADE中的信号更强,且ADE发生时间更早,提示临床应加强儿童患者用药后的早期安全监测.

Objective:Based on the U.S.Food and Drug Administration Adverse Event Reporting System(FAERS),this study compared the occurrence characteristics and risk signal differences of adverse drug event(ADE)associated with omalizumab between pediatric and adult asthma patients,aiming to provide more specific guidance for clinical safe medication.Methods:ADE reports related to omalizumab used for asthma treatment from January 2004 to March 2025 were retrieved from the FAERS database.ADE were described and classified using preferred term(PT)and system organ category(SOC)according to the Medical Dictionary for Regulatory Activities,version 28.0.Risk signal mining was performed using the reporting odds ratio(ROR),proportional reporting ratio(PRR),Bayesian confidence propagation neural network(BCPNN),and multi-item gamma Poisson shrinker(MGPS).Results:A total of 15 141 ADE reports were included.At the SOC level,omalizumab-related ADE in both pediatric and adult patients involved 27 SOC.Positive signals meeting all four algorithms were identified for"immune system disorders"and"respiratory,thoracic and mediastinal disorders,"and the signal values for"immune system disorders"were higher in children than in adults across all four algorithms.At the PT level,the most significant differences in ROR positive signals were observed for"anaphylactic reaction,immediate"in children and"blood pressure increased"in adults.The median time to ADE onset was 54 days in children and 97 days in adults.Conclusion:There are differences in the signal characteristics and time to onset of ADE associated with omalizumab between pediatric and adult asthma patients.Children exhibit stronger signals in immune system-and respiratory system-related ADE,with an earlier onset time,suggesting that early safety monitoring should be strengthened for pediatric patients after medication administration.

杨蕾;樊长娥;蔡惠娇;甄华;常海良;冯海先

呼和浩特市第一医院药剂科,呼和浩特 010030呼和浩特市第一医院变态反应中心,呼和浩特 010030呼和浩特市第一医院变态反应中心,呼和浩特 010030呼和浩特市第一医院药剂科,呼和浩特 010030呼和浩特市第一医院药剂科,呼和浩特 010030呼和浩特市中医蒙医医院药剂科,呼和浩特 010030

医药卫生

奥马珠单抗儿童成人药物不良事件FAERS数据库哮喘

omalizumabchildrenadultsadverse drug reactionsFAERS databaseasthma

《中国合理用药探索》 2026 (8)

6-12,7

内蒙古自治区首府地区公立医院高水平临床专科建设科技项目(2024SGGZ139)内蒙古医学科学院公立医院科研联合项目(2024GLLH0414)

10.3969/j.issn.2096-3327.2026.08.002

评论